GKOSGlaukos Corporation
$165.63+98% 1Y
$165.63
$74.6752 weeks$189.58
The financials
Glaukos Corporation by the numbers
Glaukos Corporation (GKOS) reported revenue of $186M in Q2 2026 (quarter ended Jun 30, 2026), up 50% from the same quarter a year earlier. That came with a gross margin of 82% and net loss of $18M. For the full year FY2025, revenue was $507M (+32% year on year) and net income −$188M. Its largest product in Q2 2026 was Glaucoma at $119M, 81% of the disclosed total, well ahead of Corneal Health at 19%. The next results filing is expected around Oct 28, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $186M | $124M | +50% |
| Gross profit | $152M | $97M | +56% |
| Operating income | −$17M | −$23M | n/a |
| Net income | −$18M | −$20M | n/a |
| Diluted EPS | −$0.31 | −$0.34 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Glaucoma | $119M | 81% |
| Corneal Health | $28M | 19% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $146.7M (+31%)
Glaucoma grew +64% year on yearCorneal Health +55% year on year
Segment Latestquarter on quarteryear on year
- Glaucoma$118.5M$118.5Mquarter on quarter +27%year on year +64%+27%+64%
- Corneal Health$28.2M$28.2Mquarter on quarter +49%year on year +55%+49%+55%